TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12492739

Group type: EXPERIMENTAL
Intervention: Triple therapy (proton pump inhibitor plus amoxicillin and clarithromycin for 1 week)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Proton pump inhibitor alone for 8 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Triple therapy (for ulcers of < 1.0 cm)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Proton pump inhibitor alone (for ulcers of < 1.0 cm)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Triple therapy (for ulcers of 1.0 to < 1.5 cm)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Proton pump inhibitor alone (for ulcers of 1.0 to < 1.5 cm)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Triple therapy (for ulcers of > or = 1.5 cm)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Proton pump inhibitor alone (for ulcers of > or = 1.5 cm)
Number of subjects: 120
Study: 10865302

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (75, 150, or 225 mg/d)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 9107153

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 7902034

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rocuronium 1.2 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Succinylcholine 1.0 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg and 0.9 mg/kg
Number of subjects: 50
Study: 3030619

Group type: EXPERIMENTAL
Intervention: Guar gum (mean dose: 29 g)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Wheat bran (mean dose: 33 g)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Run-in period (white flour bread)
Number of subjects: 28
Study: 29574039

Group type: EXPERIMENTAL
Intervention: E39 peptide vaccine (500 μg or 1000 μg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E39 followed by E39' (500 μg or 1000 μg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E39' followed by E39 (500 μg or 1000 μg)
Number of subjects: 0
Study: 28723717

Group type: EXPERIMENTAL
Intervention: High-frequency localized muscle vibration (LMV) at 150 Hz using a commercial device VIBRA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Neuromuscular electrical stimulation
Number of subjects: 30
Study: 26367306

Group type: EXPERIMENTAL
Intervention: Analogy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explicit light (reduced informational load)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional explicit (large informational load)
Number of subjects: 0
Study: 24028724

Group type: EXPERIMENTAL
Intervention: EBUS‐TBNA (group B)
Number of subjects: 264

Group type: COMPARATOR
Intervention: TBNA (group A)
Number of subjects: 264

Group type: COMPARATOR
Intervention: TBNA (group C1)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: EBUS‐TBNA (group C2)
Number of subjects: 264
Study: 21933563

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 120
Study: 17641927

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 65
Study: 16611719

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA) in patients with CKD
Number of subjects: 84

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 84
Study: 12958324

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus with retinopathy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus without retinopathy
Number of subjects: 30
Study: 11010060

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 0.5% ophthalmic solution, instilled four times daily for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levocabastine 0.05%, instilled four times daily for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ketorolac tromethamine vehicle, instilled four times daily for 6 weeks
Number of subjects: 0
Study: 8617884

Group type: EXPERIMENTAL
Intervention: Adenovirus vector encoding cystic fibrosis transmembrane conductance regulator, administered to the nasal epithelium with five escalating doses of up to 10(10) infectious units.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adenovirus vector encoding cystic fibrosis transmembrane conductance regulator, administered to the nasal epithelium.
Number of subjects: 0
Study: 1306646

Group type: EXPERIMENTAL
Intervention: High-dose intravenous immune globulin (HDivIG) therapy at 500 mg/kg for a 2-hour period
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional treatment including phototherapy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High-dose intravenous immune globulin (HDivIG) therapy
Number of subjects: 32
Study: 6378236

Group type: EXPERIMENTAL
Intervention: Oral acyclovir (200 mg four times daily for six weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 29361285

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy (Simvastatin and Ezetimibe)
Number of subjects: 1873

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1873
Study: 25710082

Group type: EXPERIMENTAL
Intervention: Compression rate of 120 beats/min
Number of subjects: 38

Group type: COMPARATOR
Intervention: Compression rate of 100 beats/min
Number of subjects: 38

Group type: COMPARATOR
Intervention: Compression rate of 160 beats/min
Number of subjects: 38
Study: 25728553

Group type: EXPERIMENTAL
Intervention: Cortical screws (CS)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Pedicle screws (PS)
Number of subjects: 79
Study: 23981370

Group type: EXPERIMENTAL
Intervention: MMT+AA
Number of subjects: 97

Group type: COMPARATOR
Intervention: MMT
Number of subjects: 97
Study: 21043369

Group type: EXPERIMENTAL
Intervention: Intravaginal gel (Prepidil)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Intravaginal pessary (Propess)
Number of subjects: 151
Study: 18668014

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 16563861

Group type: EXPERIMENTAL
Intervention: Self-massage and skin care using a cream containing aromatherapy oils
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-massage and skin care using a cream without aromatherapy oils
Number of subjects: 0
Study: 14990779

Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Number of subjects: 0
Study: 11407868

Group type: EXPERIMENTAL
Intervention: Nutritional intervention to increase protein and energy intake
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Nutritional intervention group
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study: 9406295

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg intravenously)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no steroids)
Number of subjects: 16
Study: 7956628

Group type: EXPERIMENTAL
Intervention: Telephone-delivered intervention (TDI)
Number of subjects: 275
Study: 3259683

Group type: EXPERIMENTAL
Intervention: Chronic spinal cord stimulation at optimal parameters for 2 months
Number of subjects: 8

Group type: COMPARATOR
Intervention: Chronic spinal cord stimulation at placebo parameters for 2 months
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Overall stimulation (both optimal and placebo)
Number of subjects: 8
Study: 29776815

Group type: EXPERIMENTAL
Intervention: Quadriceps tendon (QT) autograft
Number of subjects: 56

Group type: COMPARATOR
Intervention: Hamstring tendon (HT) autograft
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both HT and QT autografts
Number of subjects: 56
Study: 26718578

Group type: EXPERIMENTAL
Intervention: 10,400 IU cholecalciferol daily for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: 800 IU cholecalciferol daily for 6 months
Number of subjects: 40
Study: 24456999

Group type: EXPERIMENTAL
Intervention: Stand still …, and move on intervention
Number of subjects: 97
Study: 22325594

Group type: EXPERIMENTAL
Intervention: Computer delivered substance abuse and depression intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Computer-delivered typing tutorial
Number of subjects: 0
Study: 20375930

Group type: EXPERIMENTAL
Intervention: Computerized alert advising general practitioners to discuss chlamydia testing
Number of subjects: 68

Group type: COMPARATOR
Intervention: No alert (control group)
Number of subjects: 68
Study: 17919763

Group type: EXPERIMENTAL
Intervention: Glimepiride 3mg (morning) and insulin glargine (bedtime) with dose titration
Number of subjects: 100
Study: 15520831

Group type: EXPERIMENTAL
Intervention: Children with 22q11DS
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sibling controls
Number of subjects: 21
Study: 12593612

Group type: EXPERIMENTAL
Intervention: Endoscopic insertion of VP shunt
Number of subjects: 393

Group type: COMPARATOR
Intervention: Nonendoscopic insertion of VP shunt
Number of subjects: 393
Study: 10392329

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg and 10 mg, diltiazem 200 mg and 300 mg, mibefradil 50 mg and 100 mg
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Mibefradil (low dose)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Mibefradil (high dose)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Mibefradil
Number of subjects: 335
Study: 8888913

Group type: EXPERIMENTAL
Intervention: Dietary iron intake
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Oral iron therapy for adolescents with s-ferritin < 12 micrograms l-1
Number of subjects: 394

Group type: COMPARATOR
Intervention: s-ferritin levels
Number of subjects: 394

Group type: COMPARATOR
Intervention: s-ferritin and transferrin saturation correlation
Number of subjects: 394

Group type: COMPARATOR
Intervention: Mean serum ferritin concentration
Number of subjects: 394
Study: 1986667

Group type: EXPERIMENTAL
Intervention: Budesonide (400 micrograms twice daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 16
Study: 6852361

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (20 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Codeine (20 mg)
Number of subjects: 16
Study: 30753216

Group type: EXPERIMENTAL
Intervention: Preferred healthcare facility for chest pain
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Awareness of cardiac causes of chest pain
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Gender differences in hospital preference
Number of subjects: 718
Study: 29633583

Group type: EXPERIMENTAL
Intervention: Total steps·day‐1 at 18 months
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: BOUT‐MVPA steps·day‐1 at 18 months
Number of subjects: 260
Study: 27503018

Group type: EXPERIMENTAL
Intervention: Reward system (Group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine treatment (Group A)
Number of subjects: 100
Study: 26035251

Group type: EXPERIMENTAL
Intervention: Phenylephrine administration
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Nitroprusside administration
Number of subjects: 34
Study: 22412169

Group type: EXPERIMENTAL
Intervention: Chinese lacto-vegetarian diet
Number of subjects: 295

Group type: COMPARATOR
Intervention: Omnivore diet
Number of subjects: 295
Study: 20075385

Group type: EXPERIMENTAL
Intervention: Disease management program (single 1- to 1.5-hour education session, action plan for self-treatment of exacerbations, monthly follow-up calls)
Number of subjects: 743

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Disease management program
Number of subjects: 743
Study: 18578170

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide solution (Opalescence)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 22% carbamide peroxide solution (Nite White Excel 3)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Tap water (control)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Reservoirs in custom trays
Number of subjects: 96
Study: 16055224

Group type: EXPERIMENTAL
Intervention: Matrix-in-cylinder system (80 mg propranolol hydrochloride)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Matrix-in-cylinder system (80 mg propranolol hydrochloride) under fed conditions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Matrix-in-cylinder system (80 mg propranolol hydrochloride) under fasted conditions
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inderal (commercial pellet formulation)
Number of subjects: 10
Study: 11943418

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 10356104

Group type: EXPERIMENTAL
Intervention: Aspirin alone or in combination with low doses of warfarin
Number of subjects: 2012

Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 2012

Group type: EXPERIMENTAL
Intervention: Regular consumption of >/=14 alcohol-containing drinks per week
Number of subjects: 2012

Group type: EXPERIMENTAL
Intervention: Estrogen hormone replacement therapy among SPAF III participants
Number of subjects: 2012

Group type: EXPERIMENTAL
Intervention: Risk stratification scheme based on identified factors
Number of subjects: 2012

Group type: EXPERIMENTAL
Intervention: Low-risk participants
Number of subjects: 2012
Study: 7489455

Group type: EXPERIMENTAL
Intervention: Sniff Position Pillow (SPP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Shoulder Elevation (SE)
Number of subjects: 21
Study: 1954814

Group type: EXPERIMENTAL
Intervention: Usual insulin (isoglycemic study)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Omitting morning short‐acting insulin (hyperglycemic study)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nondiabetic subjects
Number of subjects: 20
Study: 6328390

Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ampicillin (ticarcillin or cloxacillin) and gentamicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 0
Study: 30733088

Group type: EXPERIMENTAL
Intervention: Provider communication intervention
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Very strong recommendation
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Presumptive recommendation
Number of subjects: 777

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 777
Study: 29562932

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary measures
Number of subjects: 0
Study: 27765365

Group type: EXPERIMENTAL
Intervention: Oligopin (OP) 75 mg, 2 capsules/day for 5 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 24997315

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 1651

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 1651

Group type: EXPERIMENTAL
Intervention: Both metronidazole and clarithromycin
Number of subjects: 1651

Group type: EXPERIMENTAL
Intervention: Prior unsuccessful eradication treatments
Number of subjects: 1651

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 1651

Group type: EXPERIMENTAL
Intervention: Country or continent of origin
Number of subjects: 1651
Study: 22994843

Group type: EXPERIMENTAL
Intervention: DELFIN parenting program
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 20402873

Group type: EXPERIMENTAL
Intervention: GlideScope Video Laryngoscope
Number of subjects: 18

Group type: COMPARATOR
Intervention: Direct Laryngoscopy
Number of subjects: 18
Study: 22117707

Group type: EXPERIMENTAL
Intervention: Adapted bone drilling method (test group)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard drilling protocol (control group)
Number of subjects: 29
Study: 16210486

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV), two doses in a 4- to 6-week interval, followed by a booster dose of 23-valent polysaccharide vaccine (PPV) after one year
Number of subjects: 33

Group type: COMPARATOR
Intervention: 23-valent polysaccharide vaccine (PPV), two doses in a 1-year interval
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: PCV priming
Number of subjects: 33
Study: 12227126

Group type: EXPERIMENTAL
Intervention: Anti-osteoporosis interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in bone density
Number of subjects: 0
Study: 9868644

Group type: EXPERIMENTAL
Intervention: 400‐mg once‐weekly fluconazole
Number of subjects: 636

Group type: COMPARATOR
Intervention: 200‐mg daily fluconazole
Number of subjects: 636
Study: 7993990

Group type: EXPERIMENTAL
Intervention: 750 mg pyrantel pamoate tablet formulation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 750 mg pyrantel pamoate suspension formulation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 750 mg pyrantel pamoate other formulation
Number of subjects: 9

Group type: COMPARATOR
Intervention: All formulations
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 9
Study: 3197751

Group type: EXPERIMENTAL
Intervention: Oral ketanserin 40 mg b.d. for two months
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral ketanserin treatment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 14
Study: 31250938

Group type: EXPERIMENTAL
Intervention: DOMUS intervention (accelerated transition from oncological to specialist palliative care)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: DOMUS intervention
Number of subjects: 38
Study: 30407361

Group type: EXPERIMENTAL
Intervention: Visual biofeedback balance training
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Lateral wedge insoles (5°)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (usual rehabilitation program)
Number of subjects: 56
Study: 26772624

Group type: EXPERIMENTAL
Intervention: NHCPlus
Number of subjects: 229

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 229
Study: 25563311

Group type: EXPERIMENTAL
Intervention: BUD plus oral MONT (10 μg, qn) for 4 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Inhaled BUD (200 μg, bid) for 4 weeks
Number of subjects: 65
Study: 23499539

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Expiratory muscle training
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined inspiratory and expiratory muscle training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (lower limb muscle exercise only)
Number of subjects: 40
Study: 20856190

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors (specific dosage and duration not mentioned)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Brain perfusion [(99m)Tc]ECD / SPECT and structural MRI
Number of subjects: 16
Study: 17976988

Group type: EXPERIMENTAL
Intervention: Capecitabine 1250 mg/m² orally bid days 1-14
Number of subjects: 47

Group type: COMPARATOR
Intervention: Vinorelbine 30 mg/m² i.v. days 1 and 8
Number of subjects: 47
Study: 15703953

Group type: EXPERIMENTAL
Intervention: Hyaluronan (HA) alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hyaluronan (HA) with corticosteroid (triamcinolone acetonide)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (HA alone)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (HA with corticosteroid)
Number of subjects: 40
Study: 12510181

Group type: EXPERIMENTAL
Intervention: Electrical acupuncture therapy via adhesive surface electrodes and auricular acupuncture therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rehabilitation therapy
Number of subjects: 100
Study: 10824627

Group type: EXPERIMENTAL
Intervention: TS-943
Number of subjects: 36
Study: 8944408

Group type: EXPERIMENTAL
Intervention: Chlorpromazine 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam 0.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1629823

Group type: EXPERIMENTAL
Intervention: High dose intravenous methotrexate (MTX) (500 mg/m2) followed by oral leucovorin every 2 weeks for up to 6 months
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low dose MTX after the high dose protocol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study: 6748672

Group type: EXPERIMENTAL
Intervention: Distilled spirits
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Beer
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (corresponding to distilled spirits)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (corresponding to beer)
Number of subjects: 64
Study: 30217604

Group type: COMPARATOR
Intervention: Lateral tarsal strip alone with non-invasive stenting of the punctum
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lateral tarsal strip with three-snip punctoplasty
Number of subjects: 40
Study: 26663908

Group type: EXPERIMENTAL
Intervention: Overweight prevalence based on CDC criteria
Number of subjects: 6574

Group type: EXPERIMENTAL
Intervention: Overweight prevalence based on IOTF criteria
Number of subjects: 6574

Group type: EXPERIMENTAL
Intervention: Overweight prevalence based on WHO criteria
Number of subjects: 6574

Group type: EXPERIMENTAL
Intervention: Obesity prevalence based on CDC criteria
Number of subjects: 6574

Group type: EXPERIMENTAL
Intervention: Obesity prevalence based on IOTF criteria
Number of subjects: 6574

Group type: EXPERIMENTAL
Intervention: Obesity prevalence based on WHO criteria
Number of subjects: 6574
Study: 24598599

Group type: EXPERIMENTAL
Intervention: Whole-grain diet
Number of subjects: 61

Group type: COMPARATOR
Intervention: Refined cereal diet (control)
Number of subjects: 61
Study: 21985079

Group type: EXPERIMENTAL
Intervention: Fast track care
Number of subjects: 400
Study: 20477825

Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection in saline (TURIS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Monopolar transurethral resection of the prostate (TURP)
Number of subjects: 100